Brief: Roivant Announces Positive Neptune Study Results For Brepocitinib In NIU

Sumitomo Pharma

02/04/2024 12:00

April 2 (Reuters) - Roivant Sciences Ltd  ROIV.O :
    * ROIVANT: POSITIVE NEPTUNE STUDY RESULTS FOR BREPOCITINIB
IN NIU
    * ROIVANT: AUTHORIZATION FOR UP TO $1.5 BILLION SHARE
REPURCHASE
PROGRAM, INCLUDING REPURCHASE OF ENTIRE SUMITOMO PHARMA STAKE
FOR $648 MILLION
    * ROIVANT: PHASE 2 NEPTUNE STUDY SECONDARY EFFICACY
ENDPOINTS WERE
POSITIVE AND DOSE RESPONSIVE
    * ROIVANT: REPURCHASE OF ALL 71.3 MILLION SHARES HELD BY
SUMITOMO
PHARMA AT PURCHASE PRICE OF $9.10 PER SHARE
    * ROIVANT: BREPOCITINIB WAS GENERALLY SAFE AND
WELL-TOLERATED IN
STUDY
    * ROIVANT: PRIOVANT THERAPEUTICS INTENDS TO INITIATE A PHASE
3
PROGRAM IN NIU IN H2 2024
    * ROIVANT: ONGOING PHASE 3 STUDY EVALUATING BREPOCITINIB IN
DERMATOMYOSITIS EXPECTED TO BE FULLY ENROLLED IN Q3 2024, DATA
EXPECTED IN 2025
    * ROIVANT: BREPOCITINIB WELL-POSITIONED TO SUPPORT POTENTIAL
MULTI-BLOCKBUSTER FRANCHISE IN SPECIALTY AUTOIMMUNITY

Source text for Eikon:  ID: 
Further company coverage:  ROIV.O 

 ((Reuters.Briefs@thomsonreuters.com;))